{
    "nctId": "NCT00077857",
    "briefTitle": "A Study to Assess Capecitabine (Xeloda\u00ae) in Patients With Locally Advanced or Metastatic Breast Cancer",
    "officialTitle": "A Randomized, Open-label Study of the Effect of Different Dosing Regimens of Xeloda\u00ae in Combination With Taxotere\u00ae on Disease Progression in Patients With Locally Advanced and/or Metastatic Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 470,
    "primaryOutcomeMeasure": "Time to Progression of Disease or Death",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* women \\>=18 years of age;\n* \\>=1 target lesion;\n* locally advanced or metastatic breast cancer;\n* demonstrated resistance to anthracycline;\n* \\>=2 regimens of chemotherapy for advanced/metastatic disease.\n\nExclusion Criteria:\n\n* previous treatment with Xeloda, continuous 5-fluorouracil infusion, or other oral fluoropyrimidines;\n* previous treatment with paclitaxel or docetaxel for advanced/metastatic disease.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}